Paramita Sen
Eli Lilly (United States) · 36 works · 1,612 citations · h-index 9
Top works
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
- Genes induced by a high-oxygen environment in Entamoeba histolytica
- Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3.
- BM-32 * CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL
- E-rosetting cells in amoebic liver abscess.
- PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
- A multicenter, nonrandomized, open-label, single-arm phase 2 trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer
- Sonographic Evaluation of Operability of Malignant Cervical Lymph Nodes
- Enhancement of virulence of Entamoeba histolytica by histamine in vitro.
- Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
- Two Phase III Studies Evaluating Ceritinib in Patients (Pts) with Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): Ascend-4 and Ascend-5
- Role of Excretory-Secretory Products of Entamoeba histolytica in Human Amebiasis
- Phagocytic function in amoebiasis.
- Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
- Assessing the incidence and severity of drug adverse events: a Bayesian hierarchical cumulative logit model
- P3.02a-025 PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4)
- First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
- Effect of exogenous 5-hydroxytryptamine on pathogenicity of Entamoeba histolytica in experimental animals.